	US 12,343,403 B2
	Targeted ligand-payload based drug delivery for cell therapy
Philip S. Low, West Lafayette, IN (US); Madduri Srinivasarao, West Lafayette, IN (US); and Boning Zhang, West Lafayette, IN (US)
Assigned to Purdue Research Foundation, West Lafayette, IN (US)
Appl. No. 16/486,632
Filed by Purdue Research Foundation, West Lafayette, IN (US)
PCT Filed Feb. 17, 2018, PCT No. PCT/US2018/018557 § 371(c)(1), (2) Date Aug. 16, 2019, PCT Pub. No. WO2018/152451, PCT Pub. Date Aug. 23, 2018.
Claims priority of provisional application 62/460,118, filed on Feb. 17, 2017.
Prior Publication US 2020/0054676 A1, Feb. 20, 2020
Int. Cl. A61K 47/66 (2017.01); A61K 40/10 (2025.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/42 (2025.01); A61K 47/69 (2017.01); C07K 14/725 (2006.01); C12N 9/90 (2006.01); C12N 15/62 (2006.01); A61K 38/00 (2006.01)

CPC A61K 47/66 (2017.08) [A61K 40/10 (2025.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/4211 (2025.01); A61K 47/6901 (2017.08); C07K 14/7051 (2013.01); C12N 9/90 (2013.01); C12N 15/62 (2013.01); A61K 38/00 (2013.01); A61K 2239/31 (2023.05); A61K 2239/38 (2023.05); A61K 2239/48 (2023.05); C07K 2319/03 (2013.01); C07K 2319/20 (2013.01); C07K 2319/912 (2013.01); C12Y 502/01008 (2013.01)]

48 Claims

1. A drug delivery platform for cell therapy comprising:

an engineered protein on a target cell for transplant, wherein the engineered protein is selected from the group consisting of SEQ ID NOS: 1 and 2;

a small molecule ligand conjugated to a linker, wherein the small molecule ligand has intrinsic high affinity to the engineered protein; and

at least one payload of drug conjugated to the linker, wherein the at least one payload of drug is associated with the target cell when the small molecule ligand binds to the engineered protein.